Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Front Cell Infect Microbiol ; 13: 1170763, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37325510

RESUMEN

The larval stage of the cestode Echinococcus multilocularis is the causative agent of alveolar echinococcosis. To investigate the biology of these stages and to test novel compounds, metacestode cultures represent a suitable in vitro model system. These metacestodes are vesicles surrounded by an envelope formed by the vesicle tissue (VT), which is formed by the laminated and germinal layer, and filled with vesicle fluid (VF). We analyzed the proteome of VF and VT by liquid chromatography tandem mass spectrometry (LC-MS/MS) and identified a total of 2,954 parasite proteins. The most abundant protein in VT was the expressed conserved protein encoded by EmuJ_000412500, followed by the antigen B subunit AgB8/3a encoded by EmuJ_000381500 and Endophilin B1 (protein p29). In VF, the pattern was different and dominated by AgB subunits. The most abundant protein was the AgB8/3a subunit followed by three other AgB subunits. In total, the AgB subunits detected in VF represented 62.1% of the parasite proteins. In culture media (CM), 63 E. multilocularis proteins were detected, of which AgB subunits made up 93.7% of the detected parasite proteins. All AgB subunits detected in VF (encoded by EmuJ_000381100-700, corresponding to AgB8/2, AgB8/1, AgB8/4, AgB8/3a, AgB8/3b, and AgB8/3c) were also found in CM, except the subunit encoded by EmuJ_000381800 (AgB8/5) that was very rare in VF and not detected in CM. The relative abundance of the AgB subunits in VF and CM followed the same pattern. In VT, only the subunits EmuJ_000381500 (AgB8/3a) and EmuJ_000381200 (AgB8/1) were detected among the 20 most abundant proteins. To see whether this pattern was specific to VF from in vitro cultured metacestodes, we analyzed the proteome of VF from metacestodes grown in a mouse model. Here, the AgB subunits encoded by EmuJ_000381100-700 constituted the most abundant proteins, namely, 81.9% of total protein, with the same order of abundance as in vitro. Immunofluorescence on metacestodes showed that AgB is co-localized to calcareous corpuscles of E. multilocularis. Using targeted proteomics with HA-tagged EmuJ_000381200 (AgB8/1) and EmuJ_000381100 (AgB8/2), we could show that uptake of AgB subunits from CM into VF occurs within hours.


Asunto(s)
Echinococcus multilocularis , Parásitos , Animales , Ratones , Proteómica , Proteoma , Cromatografía Liquida , Espectrometría de Masas en Tándem
2.
Int J Parasitol Drugs Drug Resist ; 21: 114-124, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36921443

RESUMEN

Alveolar echinococcosis (AE) is caused by infection with the fox tapeworm E. multilocularis. The disease affects humans, dogs, captive monkeys, and other mammals, and it is caused by the metacestode stage of the parasite growing invasively in the liver. The current drug treatment is based on non-parasiticidal benzimidazoles. Thus, they are only limitedly curative and can cause severe side effects. Therefore, novel and improved treatment options for AE are needed. Mefloquine (MEF), an antimalarial agent, was previously shown to be effective against E. multilocularis in vitro and in experimentally infected mice. However, MEF is not parasiticidal and needs improvement for successful treatment of patients, and it can induce strong neuropsychiatric side-effects. In this study, the structure-activity relationship and mode of action of MEF was investigated by comparative analysis of 14 MEF derivatives. None of them showed higher activity against E. multilocularis metacestodes compared to MEF, but four compounds caused limited damage. In order to identify molecular targets of MEF and effective derivatives, differential affinity chromatography combined with mass spectrometry was performed with two effective compounds (MEF, MEF-3) and two ineffective compounds (MEF-13, MEF-22). 1'681 proteins were identified that bound specifically to MEF or derivatives. 216 proteins were identified as binding only to MEF and MEF-3. GO term enrichment analysis of these proteins and functional grouping of the 25 most abundant MEF and MEF-3 specific binding proteins revealed the key processes energy metabolism and cellular transport and structure, as well as stress responses and nucleic acid binding to be involved. The previously described ferritin was confirmed as an exclusively MEF-binding protein that could be relevant for its efficacy against E. multilocularis. The here identified potential targets of MEF will be further investigated in the future for a clear understanding of the pleiotropic effects of MEF, and improved therapeutic options against AE.


Asunto(s)
Equinococosis , Echinococcus multilocularis , Parásitos , Humanos , Ratones , Animales , Perros , Mefloquina/farmacología , Mefloquina/uso terapéutico , Equinococosis/tratamiento farmacológico , Equinococosis/parasitología , Antiparasitarios/farmacología , Mamíferos
3.
Sci Rep ; 12(1): 20938, 2022 12 03.
Artículo en Inglés | MEDLINE | ID: mdl-36463282

RESUMEN

Studies in mice have shown that less aversive handling methods (e.g. tunnel or cup handling) can reduce behavioural measures of anxiety in comparison to picking mice up by their tail. Despite such evidence, tail handling continues to be used routinely. Besides resistance to change accustomed procedures, this may also be due to the fact that current evidence in support of less aversive handling is mostly restricted to effects of extensive daily handling, which may not apply to routine husbandry practices. The aim of our study was to assess whether, and to what extent, different handling methods during routine husbandry induce differences in behavioural and physiological measures of stress in laboratory mice. To put the effects of handling method in perspective with chronic stress, we compared handling methods to a validated paradigm of unpredictable chronic mild stress (UCMS). We housed mice of two strains (Balb/c and C57BL/6) and both sexes either under standard laboratory conditions (CTRL) or under UCMS. Half of the animals from each housing condition were tail handled and half were tunnel handled twice per week, once during a cage change and once for a routine health check. We found strain dependent effects of handling method on behavioural measures of anxiety: tunnel handled Balb/c mice interacted with the handler more than tail handled conspecifics, and tunnel handled CTRL mice showed increased open arm exploration in the elevated plus-maze. Mice undergoing UCMS showed increased plasma corticosterone levels and reduced sucrose preference. However, we found no effect of handling method on these stress-associated measures. Our results therefore indicate that routine tail handling can affect behavioural measures of anxiety, but may not be a significant source of chronic husbandry stress. Our results also highlight strain dependent responses to handling methods.


Asunto(s)
Trastornos de Ansiedad , Enfermedad Injerto contra Huésped , Femenino , Masculino , Ratones , Animales , Ratones Endogámicos C57BL , Ansiedad , Prueba de Laberinto Elevado , Afecto , Ratones Endogámicos BALB C
4.
PLoS Biol ; 20(10): e3001837, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-36269766

RESUMEN

The phenotype of an organism results from its genotype and the influence of the environment throughout development. Even when using animals of the same genotype, independent studies may test animals of different phenotypes, resulting in poor replicability due to genotype-by-environment interactions. Thus, genetically defined strains of mice may respond differently to experimental treatments depending on their rearing environment. However, the extent of such phenotypic plasticity and its implications for the replicability of research findings have remained unknown. Here, we examined the extent to which common environmental differences between animal facilities modulate the phenotype of genetically homogeneous (inbred) mice. We conducted a comprehensive multicentre study, whereby inbred C57BL/6J mice from a single breeding cohort were allocated to and reared in 5 different animal facilities throughout early life and adolescence, before being transported to a single test laboratory. We found persistent effects of the rearing facility on the composition and heterogeneity of the gut microbial community. These effects were paralleled by persistent differences in body weight and in the behavioural phenotype of the mice. Furthermore, we show that environmental variation among animal facilities is strong enough to influence epigenetic patterns in neurons at the level of chromatin organisation. We detected changes in chromatin organisation in the regulatory regions of genes involved in nucleosome assembly, neuronal differentiation, synaptic plasticity, and regulation of behaviour. Our findings demonstrate that common environmental differences between animal facilities may produce facility-specific phenotypes, from the molecular to the behavioural level. Furthermore, they highlight an important limitation of inferences from single-laboratory studies and thus argue that study designs should take environmental background into account to increase the robustness and replicability of findings.


Asunto(s)
Cromatina , Ambiente , Ratones , Animales , Ratones Endogámicos C57BL , Fenotipo , Genotipo
5.
Front Immunol ; 13: 889175, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35967310

RESUMEN

Similar to human monocytes, bovine monocytes can be split into CD14highCD16- classical, CD14highCD16high intermediate and CD14-/dimCD16high nonclassical monocytes (cM, intM, and ncM, respectively). Here, we present an in-depth analysis of their steady-state bulk- and single-cell transcriptomes, highlighting both pronounced functional specializations and transcriptomic relatedness. Bulk gene transcription indicates pro-inflammatory and antibacterial roles of cM, while ncM and intM appear to be specialized in regulatory/anti-inflammatory functions and tissue repair, as well as antiviral responses and T-cell immunomodulation. Notably, intM stood out by high expression of several genes associated with antigen presentation. Anti-inflammatory and antiviral functions of ncM are further supported by dominant oxidative phosphorylation and selective strong responses to TLR7/8 ligands, respectively. Moreover, single-cell RNA-seq revealed previously unappreciated heterogeneity within cM and proposes intM as a transient differentiation intermediate between cM and ncM.


Asunto(s)
Presentación de Antígeno , Monocitos , Animales , Antivirales/metabolismo , Biología , Bovinos , Diferenciación Celular , Humanos
6.
Pathogens ; 10(10)2021 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-34684284

RESUMEN

Drug-based treatment of alveolar echinococcosis (AE) with benzimidazoles is in most cases non-curative, thus has to be taken lifelong. Here, we report on a 56-year-old male AE patient who received standard benzimidazole treatment and biliary plastic stents, and additionally self-medicated himself with the Peruvian plant extract Maca (Lepidium meyenii). After 42 months, viable parasite tissue had disappeared. Based on this striking observation, the anti-echinococcal activity of Maca was investigated in vitro and in mice experimentally infected with Echinococcus multilocularis metacestodes. Albendazole (ABZ)-treated mice and mice treated with an ABZ+Maca combination exhibited a significantly reduced parasite burden compared to untreated or Maca-treated mice. As shown by a newly established UHPLC-MS/MS-based measurement of ABZ-metabolites, the presence of Maca during the treatment did not alter ABZ plasma levels. In vitro assays corroborated these findings, as exposure to Maca had no notable effect on E. multilocularis metacestodes, and in cultures of germinal layer cells, possibly unspecific, cytotoxic effects of Maca were observed. However, in the combined treatments, Maca inhibited the activity of ABZ in vitro. While Maca had no direct anti-parasitic activity, it induced in vitro proliferation of murine spleen cells, suggesting that immunomodulatory properties could have contributed to the curative effect seen in the patient.

7.
Parasite Immunol ; 43(8): e12834, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33754355

RESUMEN

BACKGROUND: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) immune checkpoint blockade are efficacious in certain cancer therapies. OBJECTIVES: The present study aimed to provide a picture about the development of innate and adaptive immune responses upon PD-L1 blockade in treating chronic murine AE. METHODS: Immune treatment started at 6 weeks post-E. multilocularis infection, and was maintained for 8 weeks with twice per week anti-PD-L1 administration (intraperitoneal). The study included an outgroup-control with mice perorally medicated with albendazole 5 d/wk, and another one with both treatments combined. Assessment of treatment efficacy was based on determining parasite weight, innate and adaptive immune cell profiles, histopathology and liver tissue cytokine levels. RESULTS/CONCLUSIONS: Findings showed that the parasite load was significantly reduced in response to PD-L1 blockade, and this blockade (a) contributed to T-cell activity by increasing CD4+ /CD8+ effector T cells, and decreasing Tregs; (b) had the capacity to restore DCs and Kupffer cells/Macrophages; (c) suppressed NKT and NK cells; and thus (d) lead to an improved control of E. multilocularis infection in mice. This study suggests that the PD-L1 pathway plays an important role by regulating adaptive and innate immune cells against E. multilocularis infection, with significant modulation of tissue inflammation.


Asunto(s)
Antígeno B7-H1 , Equinococosis , Animales , Linfocitos T CD8-positivos , Inmunidad , Ratones , Receptor de Muerte Celular Programada 1
9.
Exp Parasitol ; 219: 108013, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33010287

RESUMEN

Alveolar echinococcosis (AE) is a deadly parasitic disease that requires lifelong treatment with albendazole. Development of host immunity is pivotal with regard to the clinical outcome of AE, but its influence on conventional albendazole treatment is unknown. Using T-cell deficient athymic nude mice, we demonstrated that functional immunity is required for albendazole to be efficacious against murine AE. These results call for attention given the increasing number of immunocompromised patients with AE.


Asunto(s)
Albendazol/uso terapéutico , Anticestodos/uso terapéutico , Equinococosis Hepática/tratamiento farmacológico , Echinococcus multilocularis/efectos de los fármacos , Albendazol/farmacología , Animales , Anticestodos/farmacología , Modelos Animales de Enfermedad , Equinococosis Hepática/inmunología , Huésped Inmunocomprometido , Ratones , Ratones Desnudos , Distribución Aleatoria
10.
Int J Parasitol Drugs Drug Resist ; 13: 121-129, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32636148

RESUMEN

The current chemotherapeutical treatment against alveolar echinococcosis relies exclusively on benzimidazoles, which are not parasiticidal and can induce severe toxicity. There are no alternative treatment options. To identify novel drugs with activity against Echinococcus multilocularis metacestodes, researchers have studied potentially interesting drug targets (e.g. the parasite's energy metabolism), and/or adopted drug repurposing approaches by undertaking whole organism screenings. We here focus on drug screening approaches, which utilize an in vitro screening cascade that includes assessment of the drug-induced physical damage of metacestodes, the impact on metacestode viability and the viability of isolated parasite stem cells, structure-activity relationship (SAR) analysis of compound derivatives, and the mode of action. Finally, once in vitro data are indicative for a therapeutic window, the efficacy of selected compounds is assessed in experimentally infected mice. Using this screening cascade, we found that the anti-malarial mefloquine was active against E. multilocularis metacestodes in vitro and in vivo. To shed more light into the mode of action of mefloquine, SAR analysis on mefloquine analogues was performed. E. multilocularis ferritin was identified as a mefloquine-binding protein, but its precise role as a drug target remains to be elucidated. In mice that were infected either intraperitoneally with metacestodes or orally with eggs, oral treatment with mefloquine led to a significant reduction of parasite growth compared to the standard treatment with albendazole. However, mefloquine was not acting parasiticidally. Assessment of mefloquine plasma concentrations in treated mice showed that levels were reached which are close to serum concentrations that are achieved in humans during long-term malaria prophylaxis. Mefloquine might be applied in human AE patients as a salvage treatment. Future studies should focus on other repurposed anti-infective compounds (MMV665807, niclosamide, atovaquone), which showed stronger in vitro activity against E. multilocularis than mefloquine.


Asunto(s)
Anticestodos/farmacología , Antimaláricos/farmacología , Reposicionamiento de Medicamentos , Echinococcus multilocularis , Mefloquina/farmacología , Albendazol/farmacología , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Equinococosis/tratamiento farmacológico , Echinococcus multilocularis/efectos de los fármacos , Echinococcus multilocularis/crecimiento & desarrollo , Echinococcus multilocularis/metabolismo , Ferritinas/efectos de los fármacos , Ferritinas/metabolismo , Humanos , Mefloquina/análogos & derivados , Ratones
11.
Sci Rep ; 9(1): 19438, 2019 12 19.
Artículo en Inglés | MEDLINE | ID: mdl-31857639

RESUMEN

Alveolar echinococcosis (AE) is a zoonotic disease that is deadly if left untreated. AE is caused by the larval metacestode stage of the cestode Echinococcus multilocularis. Better knowledge on the host-parasite interface could yield novel targets for improvement of the treatment against AE. We analyzed culture media incubated with in vitro grown E. multilocularis metacestodes by 1H nuclear magnetic resonance spectroscopy to identify the unknown metabolic footprint of the parasite. Moreover, we quantitatively analyzed all amino acids, acetate, glucose, lactate, and succinate in time-course experiments using liquid chromatography and enzymatic assays. The E. multilocularis metacestodes consumed glucose and, surprisingly, threonine and produced succinate, acetate, and alanine as major fermentation products. The metabolic composition of vesicle fluid (VF) from in vitro grown E. multilocularis metacestodes was different from parasite-incubated culture medium with respect to the abundance, but not the spectrum, of metabolites, and some metabolites, in particular amino acids, accumulated in the VF. Overall, this study presents the first characterization of the in vitro metabolic footprint of E. multilocularis metacestodes and VF composition, and it provides the basis for analyses of potentially targetable pathways for future drug development.


Asunto(s)
Echinococcus multilocularis/metabolismo , Larva/metabolismo , Animales , Anticestodos/farmacología , Anticestodos/uso terapéutico , Desarrollo de Medicamentos , Equinococosis/tratamiento farmacológico , Equinococosis/parasitología , Echinococcus multilocularis/efectos de los fármacos , Interacciones Huésped-Parásitos/efectos de los fármacos , Humanos , Larva/efectos de los fármacos , Metabolómica/métodos , Espectroscopía de Protones por Resonancia Magnética , Zoonosis/tratamiento farmacológico , Zoonosis/parasitología
12.
Food Waterborne Parasitol ; 15: e00040, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32095613

RESUMEN

The lethal disease alveolar echinococcosis (AE) is caused by the metacestode stage of the fox tapeworm Echinococcus multilocularis. Current chemotherapeutical treatment of AE relies on albendazole and mebendazole, with the caveat that these compounds are not parasiticidal. Drugs have to be taken for a prolonged period of time, often life-long, which can cause adverse effects and reduces the patients' quality of life. In some individuals, benzimidazoles are inactive or cause toxicity, leading to treatment discontinuation. Alternatives to benzimidazoles are urgently needed. Over the recent years, in vivo and in vitro models for low-to-medium throughput drug discovery against AE have been set in place. In vitro drug tests include the phosphoglucose-isomerase (PGI) assay to measure physical damage induced to metacestodes, and viability assays to assess parasiticidal activity against metacestodes and stem cells. In vitro models are also employed for studies on mechanisms of action. In vivo models are thus far based on rodents, mainly mice, and benefits could be gained in future by comparative approaches in naturally infected dogs or captive monkeys. For the identification of novel drugs against AE, a rare disease with a low expected market return, drug-repurposing is the most promising strategy. A variety of chemically synthesized compounds as well as natural products have been analyzed with respect to in vitro and/or in vivo activities against AE. We here review and discuss the most active of these compounds including anti-infective compounds (benzimidazoles, nitazoxanide, amphotericin B, itraconazole, clarithromycin, DB1127, and buparvaquone), the anti-infective anti-malarials (artemisinin, ozonids, mefloquine, and MMV665807) and anti-cancer drugs (isoflavones, 2-methoxyestradiol, methotrexate, navelbine, vincristine, kinase inhibitors, metallo-organic ruthenium complexes, bortezomib, and taxanes). Taking into account the efficacy as well as the potential availability for patients, the most promising candidates are new formulations of benzimidazoles and mefloquine. Future drug-repurposing approaches should also target the energy metabolism of E. multilocularis, in particular the understudied malate dismutation pathway, as this offers an essential target in the parasite, which is not present in mammals.

13.
Int J Parasitol Drugs Drug Resist ; 8(3): 440-450, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30396011

RESUMEN

The metacestode stage of the fox tapeworm Echinococcus multilocularis causes the lethal disease alveolar echinococcosis. Current chemotherapeutic treatment options are based on benzimidazoles (albendazole and mebendazole), which are insufficient and hence alternative drugs are needed. In this study, we screened the 400 compounds of the Medicines for Malaria Venture (MMV) Pathogen Box against E. multilocularis metacestodes. For the screen, we employed the phosphoglucose isomerase (PGI) assay which assesses drug-induced damage on metacestodes, and identified ten new compounds with activity against the parasite. The anti-theilerial drug MMV689480 (buparvaquone) and MMV671636 (ELQ-400) were the most promising compounds, with an IC50 of 2.87 µM and 0.02 µM respectively against in vitro cultured E. multilocularis metacestodes. Both drugs suggested a therapeutic window based on their cytotoxicity against mammalian cells. Transmission electron microscopy revealed that treatment with buparvaquone impaired parasite mitochondria early on and additional tests showed that buparvaquone had a reduced activity under anaerobic conditions. Furthermore, we established a system to assess mitochondrial respiration in isolated E. multilocularis cells in real time using the Seahorse XFp Analyzer and demonstrated inhibition of the cytochrome bc1 complex by buparvaquone. Mice with secondary alveolar echinococcosis were treated with buparvaquone (100 mg/kg per dose, three doses per week, four weeks of treatment), but the drug failed to reduce the parasite burden in vivo. Future studies will reveal whether improved formulations of buparvaquone could increase its effectivity.


Asunto(s)
Antiprotozoarios/farmacología , Reposicionamiento de Medicamentos/métodos , Echinococcus multilocularis/efectos de los fármacos , Naftoquinonas/farmacología , Naftoquinonas/uso terapéutico , Albendazol/farmacología , Albendazol/uso terapéutico , Animales , Antihelmínticos/farmacología , Antiprotozoarios/química , Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/uso terapéutico , Evaluación Preclínica de Medicamentos/métodos , Reposicionamiento de Medicamentos/estadística & datos numéricos , Equinococosis/tratamiento farmacológico , Echinococcus multilocularis/patogenicidad , Complejo III de Transporte de Electrones/efectos de los fármacos , Complejo III de Transporte de Electrones/farmacología , Glucosa-6-Fosfato Isomerasa/metabolismo , Concentración 50 Inhibidora , Estadios del Ciclo de Vida/efectos de los fármacos , Ratones , Microscopía Electrónica de Transmisión , Naftoquinonas/química , Carga de Parásitos , Éteres Fenílicos/farmacología , Quinolonas/farmacología
14.
Int J Parasitol Drugs Drug Resist ; 8(2): 331-340, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29933218

RESUMEN

The cestode E. multilocularis causes the disease alveolar echinococcosis (AE) in humans. The continuously proliferating metacestode (larval stage) of the parasite infects mostly the liver and exhibits tumor-like growth. Current chemotherapeutical treatment options rely on benzimidazoles, which are rarely curative and have to be applied daily and life-long. This can result in considerable hepatotoxicity and thus treatment discontinuation. Therefore, novel drugs against AE are urgently needed. The anti-malarial mefloquine was previously shown to be active against E. multilocularis metacestodes in vitro, and in mice infected by intraperitoneal inoculation of metacestodes when administered at 100 mg/kg by oral gavage twice a week for 12 weeks. In the present study, the same dosage regime was applied in mice infected via oral uptake of eggs representing the natural route of infection. After 12 weeks of treatment, the presence of parasite lesions was assessed in a liver squeeze chamber and by PCR, and a significantly reduced parasite load was found in mefloquine-treated animals. Assessment of mefloquine plasma concentrations by HPLC and modeling using a two-compartment pharmacokinetic model with first-order absorption showed that >90% of the expected steady-state levels (Cmin 1.15 mg/L, Cmax 2.63 mg/L) were reached. These levels are close to concentrations achieved in humans during long-term weekly dosage of 250 mg (dose applied for malaria prophylaxis). In vitro structure-activity relationship analysis of mefloquine and ten derivatives revealed that none of the derivatives exhibited stronger activities than mefloquine. Activity was only observed, when the 2-piperidylmethanol group of mefloquine was replaced by an amino group-containing residue and when the trifluoromethyl residue on position 8 of the quinoline structure was present. This is in line with the anti-malarial activity of mefloquine and it implies that the mode of action in E. multilocularis might be similar to the one against malaria.


Asunto(s)
Equinococosis/tratamiento farmacológico , Echinococcus multilocularis/efectos de los fármacos , Hígado/efectos de los fármacos , Mefloquina/farmacocinética , Mefloquina/uso terapéutico , Animales , Antimaláricos/administración & dosificación , Bencimidazoles/uso terapéutico , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Equinococosis/parasitología , Echinococcus multilocularis/genética , Humanos , Hígado/parasitología , Mefloquina/análogos & derivados , Mefloquina/sangre , Ratones , Carga de Parásitos , Relación Estructura-Actividad
15.
PLoS Negl Trop Dis ; 11(5): e0005618, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28520724

RESUMEN

Intestinal cestodes are infecting millions of people and livestock worldwide, but treatment is mainly based on one drug: praziquantel. The identification of new anti-cestodal compounds is hampered by the lack of suitable screening assays. It is difficult, or even impossible, to evaluate drugs against adult cestodes in vitro due to the fact that these parasites cannot be cultured in microwell plates, and adult and larval stages in most cases represent different organisms in terms of size, morphology, and metabolic requirements. We here present an in vitro-drug screening assay based on Echinococcus multilocularis protoscoleces, which represent precursors of the scolex (hence the anterior part) of the adult tapeworm. This movement-based assay can serve as a model for an adult cestode screen. Protoscoleces are produced in large numbers in Mongolian gerbils and mice, their movement is measured and quantified by image analysis, and active compounds are directly assessed in terms of morphological effects. The use of the 384-well format minimizes the amount of parasites and compounds needed and allows rapid screening of a large number of chemicals. Standard drugs showed the expected dose-dependent effect on movement and morphology of the protoscoleces. Interestingly, praziquantel inhibited movement only partially within 12 h of treatment (at concentrations as high as 100 ppm) and did thus not act parasiticidal, which was also confirmed by trypan blue staining. Enantiomers of praziquantel showed a clear difference in their minimal inhibitory concentration in the motility assay and (R)-(-)-praziquantel was 185 times more active than (S)-(-)-praziquantel. One compound named MMV665807, which was obtained from the open access MMV (Medicines for Malaria Venture) Malaria box, strongly impaired motility and viability of protoscoleces. Corresponding morphological alterations were visualized by scanning electron microscopy, and demonstrated that this compound exhibits a mode of action clearly distinct from praziquantel. Thus, MMV665807 represents an interesting lead for further evaluation.


Asunto(s)
Antihelmínticos/farmacología , Bioensayo/métodos , Evaluación Preclínica de Medicamentos/métodos , Echinococcus multilocularis/efectos de los fármacos , Echinococcus multilocularis/fisiología , Locomoción/efectos de los fármacos , Animales , Benzamidas/farmacología , Echinococcus multilocularis/anatomía & histología , Gerbillinae , Ensayos Analíticos de Alto Rendimiento/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Ratones , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica de Rastreo , Imagen Óptica/métodos , Praziquantel/farmacología
16.
PLoS Negl Trop Dis ; 10(3): e0004535, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26967740

RESUMEN

The metacestode (larval) stage of the tapeworm Echinococcus multilocularis causes alveolar echinococcosis (AE), a very severe and in many cases incurable disease. To date, benzimidazoles such as albendazole and mebendazole are the only approved chemotherapeutical treatment options. Benzimidazoles inhibit metacestode proliferation, but do not act parasiticidal. Thus, benzimidazoles have to be taken a lifelong, can cause adverse side effects such as hepatotoxicity, and are ineffective in some patients. We here describe a newly developed screening cascade for the evaluation of the in vitro efficacy of new compounds that includes assessment of parasiticidal activity. The Malaria Box from Medicines for Malaria Venture (MMV), comprised of 400 commercially available chemicals that show in vitro activity against Plasmodium falciparum, was repurposed. Primary screening was carried out at 10 µM by employing the previously described PGI assay, and resulted in the identification of 24 compounds that caused physical damage in metacestodes. Seven out of these 24 drugs were also active at 1 µM. Dose-response assays revealed that only 2 compounds, namely MMV665807 and MMV665794, exhibited an EC50 value below 5 µM. Assessments using human foreskin fibroblasts and Reuber rat hepatoma cells showed that the salicylanilide MMV665807 was less toxic for these two mammalian cell lines than for metacestodes. The parasiticidal activity of MMV665807 was then confirmed using isolated germinal layer cell cultures as well as metacestode vesicles by employing viability assays, and its effect on metacestodes was morphologically evaluated by electron microscopy. However, both oral and intraperitoneal application of MMV665807 to mice experimentally infected with E. multilocularis metacestodes did not result in any reduction of the parasite load.


Asunto(s)
Antihelmínticos/aislamiento & purificación , Antihelmínticos/farmacología , Evaluación Preclínica de Medicamentos/métodos , Reposicionamiento de Medicamentos/métodos , Equinococosis Hepática/tratamiento farmacológico , Echinococcus multilocularis/efectos de los fármacos , Animales , Antihelmínticos/toxicidad , Antimaláricos/farmacología , Antimaláricos/toxicidad , Bioensayo , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Equinococosis , Echinococcus multilocularis/anatomía & histología , Echinococcus multilocularis/fisiología , Fibroblastos/efectos de los fármacos , Fibroblastos/fisiología , Hepatocitos/efectos de los fármacos , Hepatocitos/fisiología , Ratones Endogámicos BALB C , Microscopía , Análisis de Supervivencia , Resultado del Tratamiento
17.
Int J Antimicrob Agents ; 46(5): 546-51, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26395219

RESUMEN

This study investigated the effects of oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine (MEF) and identified proteins that bind to MEF in parasite extracts and human cells by affinity chromatography. In a pilot experiment, MEF treatment was applied 5 days per week and was intensified by increasing the dosage stepwise from 12.5 mg/kg to 200 mg/kg during 4 weeks followed by treatments of 100 mg/kg during the last 7 weeks. This resulted in a highly significant reduction of parasite weight in MEF-treated mice compared with mock-treated mice, but the reduction was significantly less efficacious compared with the standard treatment regimen of albendazole (ABZ). In a second experiment, MEF was applied orally in three different treatment groups at dosages of 25, 50 or 100 mg/kg, but only twice a week, for a period of 12 weeks. Treatment at 100 mg/kg had a profound impact on the parasite, similar to ABZ treatment at 200 mg/kg/day (5 days/week for 12 weeks). No adverse side effects were noted. To identify proteins in E. multilocularis metacestodes that physically interact with MEF, affinity chromatography of metacestode extracts was performed on MEF coupled to epoxy-activated Sepharose(®), followed by SDS-PAGE and in-gel digestion LC-MS/MS. This resulted in the identification of E. multilocularis ferritin and cystatin as MEF-binding proteins. In contrast, when human cells were exposed to MEF affinity chromatography, nicotinamide phosphoribosyltransferase was identified as a MEF-binding protein. This indicates that MEF could potentially interact with different proteins in parasites and human cells.


Asunto(s)
Antihelmínticos/administración & dosificación , Equinococosis/tratamiento farmacológico , Echinococcus multilocularis/efectos de los fármacos , Mefloquina/administración & dosificación , Administración Oral , Animales , Antihelmínticos/efectos adversos , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Células CACO-2 , Cromatografía de Afinidad , Cromatografía Liquida , Cistatinas/metabolismo , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Equinococosis/parasitología , Electroforesis en Gel de Poliacrilamida , Femenino , Ferritinas/metabolismo , Humanos , Mefloquina/efectos adversos , Ratones Endogámicos BALB C , Unión Proteica , Espectrometría de Masas en Tándem , Resultado del Tratamiento
18.
Parasite ; 21: 70, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25526545

RESUMEN

The search for novel therapeutic options to cure alveolar echinococcosis (AE), due to the metacestode of Echinococcus multilocularis, is ongoing, and these developments could also have a profound impact on the treatment of cystic echinococcosis (CE), caused by the closely related Echinococcus granulosus s.l. Several options are being explored. A viable strategy for the identification of novel chemotherapeutically valuable compounds includes whole-organism drug screening, employing large-scale in vitro metacestode cultures and, upon identification of promising compounds, verification of drug efficacy in small laboratory animals. Clearly, the current focus is targeted towards broad-spectrum anti-parasitic or anti-cancer drugs and compound classes that are already marketed, or that are in development for other applications. The availability of comprehensive Echinococcus genome information and gene expression data, as well as significant progress on the molecular level, has now opened the door for a more targeted drug discovery approach, which allows exploitation of defined pathways and enzymes that are essential for the parasite. In addition, current in vitro and in vivo models that are used to assess drug efficacy should be optimized and complemented by methods that give more detailed information on the host-parasite interactions that occur during drug treatments. The key to success is to identify, target and exploit those parasite molecules that orchestrate activities essential to parasite survival.


Asunto(s)
Albendazol/uso terapéutico , Antihelmínticos/uso terapéutico , Equinococosis/tratamiento farmacológico , Mebendazol/uso terapéutico , Animales , Antihelmínticos/clasificación , Antihelmínticos/farmacología , División Celular/efectos de los fármacos , Claritromicina/farmacología , Claritromicina/uso terapéutico , Citostáticos/farmacología , Citostáticos/uso terapéutico , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Equinococosis Hepática/tratamiento farmacológico , Equinococosis Hepática/parasitología , Echinococcus multilocularis/efectos de los fármacos , Echinococcus multilocularis/crecimiento & desarrollo , Echinococcus multilocularis/fisiología , Echinococcus multilocularis/ultraestructura , Predicción , Guanidinas/uso terapéutico , Proteínas del Helminto/antagonistas & inhibidores , Interacciones Huésped-Parásitos/efectos de los fármacos , Humanos , Imidazoles/farmacología , Imidazoles/uso terapéutico , Larva/efectos de los fármacos , Mefloquina/uso terapéutico , Ratones , Terapia Molecular Dirigida , Nitrocompuestos , Tiazoles/farmacología , Tiazoles/uso terapéutico , Tiofenos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...